Eric Topol — American Scientist

Eric J. Topol is an American cardiologist, geneticist, and digital medicine researcher. Before moving to Scripps in 2006, Topol served as chairman of cardiovascular medicine at Cleveland Clinic and founded the Cleveland Clinic Lerner College of Medicine. Topol was one of the first researchers to question the cardiovascular safety of rofecoxib, culminating in the drug's ultimate withdrawal from the market. Topol's advocacy on the subject led to what the New York Times described as an "unusually public dispute" with the Cleveland Clinic's leadership over ties between the academic institution and the pharmaceutical industry, ultimately leading to Topol's departure from the Clinic after his administrative position as head of the Clinic's academic program was abolished... (wikipedia)

For people who have heart disease, statins are great. But if all you've had is high cholesterol, what you're doing is taking this 1/100 chance of getting a benefit and offsetting it with 1/200 chance of getting diabetes.
When I went to medical school, the term 'digital' applied only to rectal exams.
The digital world has been in a separate orbit from our medical cocoon, and it's time the boundaries be taken down.
I use a portable pocket ultrasound device instead of a stethoscope to listen to the heart, and I share it with the patient in real time. 'Look at your valve, look at your heart-muscle strength.' So they're looking at it with me. Normally a patient is tested by an ultrasonographer who is not allowed to tell them anything.
For diabetes in particular, we know there's a relationship between lack of glucose regulation and complications like blindness and kidney failure. So if you were diabetic and you knew that you could get your glucose in a tight, normal range just by adjusting your lifestyle, wouldn't that be great?